← All organizations
Highest phase reached
Phase 3
First clinical trial
Oct 1, 2004First marketed drug
Apr 3, 2024First NDA
Apr 3, 2024Last known activity
Aug 26, 2025
Timeline
2000s
- Jan 1, 2000
Basilea Pharmaceutica— Founded
2020s
- Apr 3, 2024
ceftobiprole— NDA Organization
Drugs by trial phase (43 distinct, 68 trials)
Phase 3 (13 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Phase 1 (25 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Aspergillosis
- Bacteremia
- Bacterial Infections
- Candidemia
- Candidiasis
- Candidiasis, Invasive
- Carcinoma, Transitional Cell
- Cellulitis
- Communicable Diseases
- Dermatitis
- Eczema
- Fever
- Glioblastoma
- Gram-Positive Bacterial Infections
- Hand Dermatoses
- Healthcare-Associated Pneumonia
- Infections
- Invasive Fungal Infections
- Kidney Failure, Chronic
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lupus Erythematosus, Cutaneous
- Lupus Erythematosus, Systemic
- Mycoses
- Neoplasms
- Neutropenia
- Pneumonia
- Pneumonia, Ventilator-Associated
- Pseudomonas Infections
- Psoriasis
- Renal Insufficiency
- Skin Diseases
- Skin Diseases, Bacterial
- Skin Diseases, Infectious
- Staphylococcal Skin Infections
- Streptococcal Infections
Marketed drugs (1)
Recent trials (50)
- NCT04087876Lead sponsorN/A—
- NCT06433128Lead sponsorN/A—
- NCT06925321Lead sponsorPhase 3Aug 26, 2025
- NCT06925321OfficialPhase 3Aug 26, 2025
- NCT06961708Lead sponsorPhase 1Apr 14, 2025
- NCT05856227OfficialPhase 3Aug 6, 2023
- NCT05856227Lead sponsorPhase 3Aug 6, 2023
- NCT04604132Study directorPhase 1/Phase 2Oct 6, 2020
- NCT04604132Lead sponsorPhase 1/Phase 2Oct 6, 2020
- NCT04098692Lead sponsorPhase 1Aug 8, 2019
- NCT04045613Lead sponsorPhase 1/Phase 2Jul 25, 2019
- NCT04045613Study directorPhase 1/Phase 2Jul 25, 2019
- NCT03439124Study directorPhase 3Nov 27, 2017
- NCT03439124Lead sponsorPhase 3Nov 27, 2017
- NCT03241550CollaboratorPhase 1Oct 2, 2017
Details
- Founded
- Basel, CH Jan 1, 2000
- First NDA
- Apr 3, 2024
- Last known activity
- Aug 26, 2025
Designations held
- Fast track
- Priority review
Notes
Spun out of Roche